New hope for kidney transplant patients: safer drug to prevent dangerous virus

NCT ID NCT07266467

First seen Jan 09, 2026 · Last updated May 01, 2026 · Updated 19 times

Summary

This study compares a new drug, leymovir, with the standard drug valganciclovir for preventing cytomegalovirus (CMV) infection in 290 Chinese kidney transplant recipients. Leymovir targets a different part of the virus, which may cause fewer side effects like low white blood cell counts and kidney damage. The goal is to see if leymovir is as effective and safer for preventing CMV disease after transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Xi 'an Jiaotong University

    RECRUITING

    Xi'an, Shaanxi, 710000, China

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.